Clinical Oncologists: Next Generation Sequencing Needs Uniform Reg Plan

A key stakeholder association is calling for FDA to regulate germline and somatic genetic testing, advocating for creation of best practices to communicate next generation sequencing test results to patients and also suggesting reimbursement policy changes that would encourage appropriate use of genetic testing. The proposals are part of an updated policy statement on next-generation sequencing, specifically for cancer susceptibility testing, clarifying the American Society for Clinical Oncologists' policy on issues pertaining to the technology and addressing two widely debated...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.